Half-Year 2022 Financial and Clinical Trials Update
PRED oncology development programs -2
Roche
Molecule
Indication
Phase
# of patients
Status
CT Identifier
Oncology
Solid tumors
|
110
FPI Q4 2019
NCT04158583
CD25 (RG6292)
Advanced and metastatic solid
Part I: FPI Q1 2021
160
NCT04642365
tumors
Part II: FPI Q4 2021
Anti-GPRC5D (RG6234)
Multiple myeloma
240
FPI Q4 2020
NCT04557150
HLA-A2-WT1 x CD3 (RG6007)
AML
|
160
FPI Q4 2020
FAP-CD40 (RG6189)
Solid tumors
280
FPI Q2 2021
HLA-A2-MAGE-A4 x CD3 (RG6129)
Solid tumors
180
FPI Q1 2022
NCT04580121
NCT04857138
NCT05129280
BRAFI (3) (RG6344)
Solid tumors
292
FPI Q1 2022
FPI Q1 2022
CD19xCD28 (RG6333)
R/R B cell non-Hodgkin's lymphoma
|
~200
ISRCTN13713
551
NCT05219513
Combination study with glofitamab
EGFRvlllxCD3 (RG6156)
Glioblastoma
~200
FPI Q2 2022
NCT05187624
151View entire presentation